Fig. 7.

Immunosuppression abrogates the antitumor effect of OVs expressing OSM. The experimental setting is as described in Fig. 6. Treatment groups (n = 6/7) included control (saline solution injection); cyclophosphamide (CP); sequential administration of Ad-OSM and NDV-OSM (Ad/NDV-OSM) and the same treatment in combination with cyclophosphamide (Ad/NDV-OSM + CP). a Progression of tumors in the different groups. Each line represents an individual hamster. The numbers indicate the number of animals with complete response/total. In the Ad/NDV-OSM group the individuals with progressive disease, partial response and complete response are indicated by red, blue and green lines, respectively. b Long-term survivors from the Ad/NDV-OSM were subjected to a subcutaneous re-challenge with HaP-T1 cells. The graphs indicate the progression of tumors in each animal. A group of untreated hamsters bearing pancreatic tumors were used as a control